|
The Board of Henderson Morley plc, the AIM listed vaccine and anti-viral drug development company, is pleased to announce the completion of studies regarding its PREPS and L-particles vaccine platform.
The studies were undertaken by a US-based contract research organisation, and examined safety, antigenicity and immunogenicity of PREPS and L-particles in laboratory models.
HIGHLIGHTS
- PREPS and L-particles demonstrated to be stable, safe, and well tolerated.
- These positive results will now lead to further studies.
- These technologies are being developed to target a number of important diseases.
PREPS and L-particles were demonstrated to be stable, safe, and well tolerated. The studies also demonstrated that a potent and dose related immune response was generated to the target antigen. These positive results will now lead to further studies examining engineered PREPS and L-particles targeted at either cancer or other model antigens.
These studies will aide the further development of PREPS and L-particles as cancer immunotherapeutic candidates. The studies will also aide with identification and selection of lead candidate vaccines.
These technologies are being developed to target a number of important diseases including virus infections in humans such as Cytomegalovirus, Epstein Barr virus and herpes simplex virus, and as a cancer immunotherapy for a wide range of different forms of human and animal cancers.
Executive Chairman Andrew Knight said: “We are delighted with the initial positive outcome of these studies. We are working on an important vaccine programme and look forward to further developing our technologies to target a wide range of diseases. |
